Response to the Letter to the Editor by Koneswarakantha and Ménard

Ther Innov Regul Sci. 2022 May;56(3):379-380. doi: 10.1007/s43441-022-00391-3. Epub 2022 Mar 11.

Authors

Silke Janitza¹, Madhurima Majumder², Franco Mendolia³, Steffen Jeske⁴, Hermann Kulmann¹

Affiliations

¹ Bayer AG, Berlin, Germany.
² Daiichi Sankyo, Inc., Basking Ridge, USA.
³ Bayer AG, Research & Development, Pharmaceuticals, Statistics and Data Insights, 42113, Wuppertal, Germany. franco.mendolia@bayer.com.
⁴ Chrestos Concept GmbH & Co. KG, Essen, Germany.

PMID: 35275362
DOI: 10.1007/s43441-022-00391-3

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment